vs

Side-by-side financial comparison of Colgate-Palmolive (CL) and US Foods Holding Corp. (USFD). Click either name above to swap in a different company.

US Foods Holding Corp. is the larger business by last-quarter revenue ($9.8B vs $5.2B, roughly 1.9× Colgate-Palmolive). US Foods Holding Corp. runs the higher net margin — 1.9% vs -0.7%, a 2.6% gap on every dollar of revenue. On growth, Colgate-Palmolive posted the faster year-over-year revenue change (5.8% vs 3.3%). Colgate-Palmolive produced more free cash flow last quarter ($1.3B vs $159.0M). Over the past eight quarters, US Foods Holding Corp.'s revenue compounded faster (4.6% CAGR vs 1.6%).

The Colgate-Palmolive Company, commonly known as Colgate-Palmolive, is an American multinational consumer products company headquartered on Park Avenue in Midtown Manhattan, New York City. The company specializes in the production, distribution, and provision of household, health care, personal care, and veterinary products.

US Foods Holding Corp. is an American food service distributor. It is the second-largest food service distributor in the U.S., after Sysco. The company supplies 250,000 locations including independent restaurants, chain restaurants, healthcare, hospitality, and educational institutions.

CL vs USFD — Head-to-Head

Bigger by revenue
USFD
USFD
1.9× larger
USFD
$9.8B
$5.2B
CL
Growing faster (revenue YoY)
CL
CL
+2.5% gap
CL
5.8%
3.3%
USFD
Higher net margin
USFD
USFD
2.6% more per $
USFD
1.9%
-0.7%
CL
More free cash flow
CL
CL
$1.1B more FCF
CL
$1.3B
$159.0M
USFD
Faster 2-yr revenue CAGR
USFD
USFD
Annualised
USFD
4.6%
1.6%
CL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CL
CL
USFD
USFD
Revenue
$5.2B
$9.8B
Net Profit
$-36.0M
$184.0M
Gross Margin
60.2%
17.6%
Operating Margin
1.7%
3.3%
Net Margin
-0.7%
1.9%
Revenue YoY
5.8%
3.3%
Net Profit YoY
-104.9%
178.8%
EPS (diluted)
$-0.04
$0.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CL
CL
USFD
USFD
Q4 25
$5.2B
$9.8B
Q3 25
$5.1B
$10.2B
Q2 25
$5.1B
$10.1B
Q1 25
$4.9B
$9.4B
Q4 24
$4.9B
$9.5B
Q3 24
$5.0B
$9.7B
Q2 24
$5.1B
$9.7B
Q1 24
$5.1B
$8.9B
Net Profit
CL
CL
USFD
USFD
Q4 25
$-36.0M
$184.0M
Q3 25
$735.0M
$153.0M
Q2 25
$743.0M
$224.0M
Q1 25
$690.0M
$115.0M
Q4 24
$738.0M
$66.0M
Q3 24
$737.0M
$148.0M
Q2 24
$731.0M
$198.0M
Q1 24
$683.0M
$82.0M
Gross Margin
CL
CL
USFD
USFD
Q4 25
60.2%
17.6%
Q3 25
59.4%
17.2%
Q2 25
60.1%
17.6%
Q1 25
60.8%
17.3%
Q4 24
60.3%
17.6%
Q3 24
61.1%
17.1%
Q2 24
60.6%
17.6%
Q1 24
60.0%
16.7%
Operating Margin
CL
CL
USFD
USFD
Q4 25
1.7%
3.3%
Q3 25
20.6%
2.8%
Q2 25
21.1%
3.7%
Q1 25
21.9%
2.4%
Q4 24
21.5%
3.2%
Q3 24
21.2%
2.9%
Q2 24
21.6%
3.6%
Q1 24
20.7%
1.8%
Net Margin
CL
CL
USFD
USFD
Q4 25
-0.7%
1.9%
Q3 25
14.3%
1.5%
Q2 25
14.5%
2.2%
Q1 25
14.1%
1.2%
Q4 24
14.9%
0.7%
Q3 24
14.6%
1.5%
Q2 24
14.5%
2.0%
Q1 24
13.5%
0.9%
EPS (diluted)
CL
CL
USFD
USFD
Q4 25
$-0.04
$0.82
Q3 25
$0.91
$0.67
Q2 25
$0.91
$0.96
Q1 25
$0.85
$0.49
Q4 24
$0.89
$0.28
Q3 24
$0.90
$0.61
Q2 24
$0.89
$0.80
Q1 24
$0.83
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CL
CL
USFD
USFD
Cash + ST InvestmentsLiquidity on hand
$1.4B
$41.0M
Total DebtLower is stronger
$7.8B
$5.1B
Stockholders' EquityBook value
$54.0M
$4.3B
Total Assets
$16.3B
$13.9B
Debt / EquityLower = less leverage
145.17×
1.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CL
CL
USFD
USFD
Q4 25
$1.4B
$41.0M
Q3 25
$1.3B
$56.0M
Q2 25
$1.2B
$61.0M
Q1 25
$1.1B
$101.0M
Q4 24
$1.3B
$59.0M
Q3 24
$1.2B
$81.0M
Q2 24
$1.1B
$405.0M
Q1 24
$1.1B
$267.0M
Total Debt
CL
CL
USFD
USFD
Q4 25
$7.8B
$5.1B
Q3 25
$4.8B
Q2 25
$4.7B
Q1 25
$4.7B
Q4 24
$7.0B
$4.8B
Q3 24
$4.7B
Q2 24
$4.6B
Q1 24
$4.6B
Stockholders' Equity
CL
CL
USFD
USFD
Q4 25
$54.0M
$4.3B
Q3 25
$856.0M
$4.5B
Q2 25
$702.0M
$4.6B
Q1 25
$363.0M
$4.6B
Q4 24
$212.0M
$4.5B
Q3 24
$435.0M
$4.6B
Q2 24
$123.0M
$5.0B
Q1 24
$230.0M
$4.8B
Total Assets
CL
CL
USFD
USFD
Q4 25
$16.3B
$13.9B
Q3 25
$17.5B
$14.0B
Q2 25
$17.5B
$13.8B
Q1 25
$16.6B
$13.7B
Q4 24
$16.0B
$13.4B
Q3 24
$16.8B
$13.5B
Q2 24
$16.5B
$13.7B
Q1 24
$16.6B
$13.4B
Debt / Equity
CL
CL
USFD
USFD
Q4 25
145.17×
1.18×
Q3 25
1.08×
Q2 25
1.02×
Q1 25
1.02×
Q4 24
33.04×
1.06×
Q3 24
1.01×
Q2 24
0.92×
Q1 24
0.95×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CL
CL
USFD
USFD
Operating Cash FlowLast quarter
$1.5B
$293.0M
Free Cash FlowOCF − Capex
$1.3B
$159.0M
FCF MarginFCF / Revenue
24.4%
1.6%
Capex IntensityCapex / Revenue
3.4%
1.4%
Cash ConversionOCF / Net Profit
1.59×
TTM Free Cash FlowTrailing 4 quarters
$3.6B
$959.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CL
CL
USFD
USFD
Q4 25
$1.5B
$293.0M
Q3 25
$1.3B
$351.0M
Q2 25
$884.0M
$334.0M
Q1 25
$600.0M
$391.0M
Q4 24
$1.3B
$283.0M
Q3 24
$1.2B
$270.0M
Q2 24
$990.0M
$482.0M
Q1 24
$681.0M
$139.0M
Free Cash Flow
CL
CL
USFD
USFD
Q4 25
$1.3B
$159.0M
Q3 25
$1.1B
$236.0M
Q2 25
$776.0M
$257.0M
Q1 25
$476.0M
$307.0M
Q4 24
$1.1B
$178.0M
Q3 24
$1.0B
$190.0M
Q2 24
$873.0M
$413.0M
Q1 24
$555.0M
$52.0M
FCF Margin
CL
CL
USFD
USFD
Q4 25
24.4%
1.6%
Q3 25
21.6%
2.3%
Q2 25
15.2%
2.5%
Q1 25
9.7%
3.3%
Q4 24
21.9%
1.9%
Q3 24
20.5%
2.0%
Q2 24
17.3%
4.3%
Q1 24
11.0%
0.6%
Capex Intensity
CL
CL
USFD
USFD
Q4 25
3.4%
1.4%
Q3 25
3.0%
1.1%
Q2 25
2.1%
0.8%
Q1 25
2.5%
0.9%
Q4 24
3.7%
1.1%
Q3 24
2.7%
0.8%
Q2 24
2.3%
0.7%
Q1 24
2.5%
1.0%
Cash Conversion
CL
CL
USFD
USFD
Q4 25
1.59×
Q3 25
1.72×
2.29×
Q2 25
1.19×
1.49×
Q1 25
0.87×
3.40×
Q4 24
1.72×
4.29×
Q3 24
1.58×
1.82×
Q2 24
1.35×
2.43×
Q1 24
1.00×
1.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CL
CL

Other$3.0B58%
Pet Nutrition$1.2B23%
Oral Personal And Home Care$1.0B20%

USFD
USFD

Product One$3.5B36%
Product Two$1.7B17%
Product Three$1.7B17%
Product Four$985.0M10%
Product Five$901.0M9%
Product Six$580.0M6%
Product Seven$485.0M5%

Related Comparisons